Health & Fitness
Health and Fitness
Health and Fitness 
Thu, March 17, 2011
Positron to Launch Automated Radiopharmaceutical System
INDIANAPOLIS--([ BUSINESS WIRE ])--Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, announced the introduction of its automated radiopharmaceutical system, under the name PosiRxa", at two upcoming industry conferences. PosiRx is the commercial name for the Companya™s automated radiopharmaceutical system, formerly referred to as Cardio-Assist during its developmental stage.
"Products such as the PosiRx will be critical in revolutionizing, simplifying and controlling procedures associated with the compounding, dispensing and distributing of radiopharmaceuticals, resulting in increased productivity, and decreased exposure and costs."
Positrona™s PosiRx system is a radiopharmaceutical system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging. Positron will introduce its PosiRx system at the upcoming American Pharmacists Association Annual Meeting and Exposition, March 25-28, in Seattle, Washington and at the American College of Cardiology April 2-5, in New Orleans, Louisiana.
aProducts such as the PosiRx will be critical in revolutionizing, simplifying and controlling procedures associated with the compounding, dispensing and distributing of radiopharmaceuticals, resulting in increased productivity, and decreased exposure and costs.a
aPosiRx offers capabilities that enhance each segment of the value chain from pharmaceutical manufacturers, pharmacya™s and ultimately the physician practice or hospital whereby improving the efficiency, economics, availability and safety of radiopharmaceutical preparation,a said Patrick G. Rooney, CEO of Positron.
The Company noted the current focus of Positrona™s PosiRx will be handling technetium 99m SPECT imaging agents which supports Positrona™s overall strategy of simplifying and improving radiopharmaceutical dose preparation and delivery. The PosiRx system provides molecular imaging departments with 24/7 unit dose accessibility, combined with the reliability of an on-site supply, and assists in compliance with all current USP-797 requirements for the production of unit dose radiopharmaceuticals.
About Positron: Positron Corporation provides unique solutions for the Nuclear Medicine community through the production and distribution of molecular imaging devices and radiopharmaceutical products. Positrona™s proprietary product lines and services include; the Attrius®, a dedicated PET imaging system; PosiStara", a world-class service and preventative maintenance customer care plan; PosiRxa", a system that automates the elution, preparation and dispensing processes for radiopharmaceutical agents used in molecular imaging; and the Tech-Assista", a PET infusion and shielding system. For more information about Positron or their products please contact us at [ www.positron.com ].
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact the CSIR Group at [ info@csirgroup.com ].